All In Biotech

Investigational drug · Phase 2

VMD-102

Also called: Single agent

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC).

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "VMD-102"

First trial start

2026

Jul 16, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "VMD-102", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Hepatocellular Carcinoma (HCC)
  • Metastatic Uveal Melanoma
  • Renal Cell Carcinoma (RCC)
  • Nonsmall Cell Lung Cancer
  • Colorectal Cancer (CRC)

Approved drugs for the same conditions: Small cell lung cancer · Colorectal cancer · Melanoma · Kidney cancer (renal cell carcinoma) · Liver cancer (hepatocellular carcinoma) · Oncology · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "VMD-102" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 21,939 on PubMed

Also in development for Hepatocellular Carcinoma (HCC)

  • SintilimabIBI308Phase 321 trials

    Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma

  • ZanzalintinibXL092Phase 311 trials

    Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • ApatinibRIVO, RivoceranibPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma

  • CamrelizumabSHR-1210, CAMPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • tinengotinibTT-00420Phase 36 trials

    TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)

  • CobolimabPhase 32 trials

    GSK · Melanoma, Hodgkin Lymphoma, High and Low Grade Glioma

  • IBI310Phase 32 trials

    Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma

  • TPST-1120Phase 32 trials

    Roche (Genentech) · Advanced Liver Cancers, Hepatocellular Carcinoma (HCC)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.